CORE ONE LABS INC - CLABF STOCK NEWS

Core One Labs Inc. has announced its acquisition of Akome Biotech Ltd., as per a share purchase agreement dated April 23, 2021. This strategic move positions Core One at the forefront of developing psychedelic therapies for neurological diseases such as Alzheimer’s, stroke, depression, and Parkinson’s. The market potential for these conditions is substantial, with projected growth in therapeutic needs. Core One will issue 3,500,000 common shares to Akome’s shareholders as part of the deal, which is not expected to constitute a change in control of Core One.

Core One Labs Inc. (OTC: CLABF) has signed a letter of intent with Lobe Sciences Ltd. to explore a joint venture for the sale and distribution of biosynthetic psilocybin. This collaboration aims to develop and market this product utilizing Lobe's patent-pending Nasal Mist Device for treating traumatic brain injuries and PTSD. Core One plans to produce cost-effective biosynthetic psilocybin, ranging between tens to hundreds of dollars per gram, significantly lower than the industry standards of $7,000 to $10,000 per gram. This strategic partnership is expected to create new revenue streams and enhance market position.

Core One Labs Inc. (OTC: CLABF) announced a letter of intent with Lobe Sciences Ltd. to form a joint venture focused on biosynthetic psilocybin. This collaboration aims to handle the production, regulatory approval, and marketing of psilocybin and other psychedelic compounds through Core One's subsidiary, Vocan Biotechnologies. The joint venture leverages Lobe's patented Nasal Mist Device for drug delivery, positioning Core One as a competitive supplier due to significantly lower production costs—projected between $10 to $100 per gram, compared to $7,000 to $10,000 for competitors.

Core One Labs Inc. (OTC: CLABF) announced a Collaborative Research Agreement with the University of British Columbia (UBC) through its subsidiary, Vocan. This partnership grants Vocan access to UBC's advanced research facilities to enhance its psilocybin production process. Utilizing recombinant synthesis with bacteria, the aim is to optimize enzyme expression for more cost-effective production. This collaboration positions Vocan favorably in the psychedelic medicines market, which is gaining traction for treating mental health disorders like depression and anxiety.

Core One Labs Inc. (OTC PINK:CLABF) has signed a Letter of Intent to acquire Akome Biotech Ltd., a developer of psychedelic-based pharmaceuticals targeting rare diseases and mental disorders like Alzheimer's and Depression. This acquisition aligns with Core One's focus on advancing psychedelic medicines, including a proprietary method to create pharmaceutical-grade psilocybin at lower costs. The global market for Alzheimer's therapeutics is expected to grow significantly, reaching USD $13.57 billion by 2027. CEO Joel Shacker emphasized the potential for growth and increased shareholder value.

Core One Labs Inc. (CSE: COOL, OTC: CLABF) has announced a Collaborative Research Agreement with the University of British Columbia (UBC) through its subsidiary, Vocan. This partnership will utilize UBC's advanced lab facilities to optimize the production of psilocybin, a psychedelic compound, using fermentation methods. The collaboration aims to enhance Vocan’s research capacity and accelerate its development in the psychedelic medicine market, which has seen growing interest for treating mental health issues such as depression and anxiety.

Core One Labs (OTC: CLABF) has initiated the design of a proprietary enzymatic production system for manufacturing API-grade DMT through its subsidiary, Vocan Biotechnologies. This innovative approach aims to enhance DMT biosynthesis compared to traditional extraction from plants. The project includes plans for a high-throughput production system and a provisional patent filing, ensuring a reliable process for producing DMT without costly chemical synthesis. This development aligns with growing research into psychedelic treatments for mental health, expanding Core One's product offerings.

Core One Labs (OTC: CLABF) announced that its subsidiary, Vocan Biotechnologies, has begun designing a proprietary enzymatic production system for API-grade DMT, a psychedelic compound under clinical investigation for mood disorders. This innovative production aims to improve DMT biosynthesis through a genetic pathway, enhancing yields compared to traditional methods. The company plans to file for a provisional patent for its production process, ensuring a reliable and cost-effective manufacturing method. Core One aims to support psychedelic research and expand its product offerings in the therapeutic space.

Core One Labs Inc. (OTC PINK:CLABF) has signed a letter of intent to acquire Akome Biotech Ltd., which specializes in psychedelic pharmaceuticals for mental health and rare diseases, including cluster headaches and Alzheimer's. This acquisition aims to enhance Core One's R&D and expand its product pipeline, potentially qualifying for orphan drug status. The deal includes issuing 3.5 million common shares to Akome's shareholders, subject to a pooling arrangement. Completion hinges on due diligence and regulatory approvals.